MarketCap
Facebook
X
Telegram
Immunome Operating Income | IMNM
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Immunome
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -224 M | -306 M | -110 M | -36.9 M | -25.2 M | -12.3 M | -10.3 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.3 M | -306 M | -103 M |
Quarterly Operating Income Immunome
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -46.5 M | -59.3 M | - | -60.1 M | -46.5 M | -44.6 M | - | -50.5 M | -40 M | -132 M | - | -4.63 M | -5.77 M | -4.47 M | - | -8.53 M | -8.93 M | -11.7 M | - | -7.72 M | -5.74 M | -3.9 M | - | -2.82 M | -2.72 M | -2.66 M | - | -2.72 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.66 M | -132 M | -26.3 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
-93.5 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-62.2 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-26.1 M | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-80.7 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-66.6 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-8.67 M | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
-31 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | USA |
 |
Generation Bio Co.
GBIO
|
-142 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-28.9 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-272 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-136 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-216 M | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
15.1 B | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-11.6 M | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
-62.1 M | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
2.84 B | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-10.3 M | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
8.17 M | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
872 M | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-68.6 M | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
10 B | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
1.19 B | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
-44.9 M | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-47.4 M | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-1.25 B | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
21.6 B | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-4.56 M | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-36.6 M | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-23.3 M | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-10.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-153 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-517 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-2.43 M | $ 0.39 | 0.15 % | $ 1.91 M | USA |
|
TFF Pharmaceuticals
TFFP
|
-21.9 M | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mirum Pharmaceuticals
MIRM
|
-22.1 M | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-68.8 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-6.16 M | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-41.7 M | $ 1.09 | 6.37 % | $ 95 M | USA |